2. Academic Validation
  3. Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

  • Clin Cancer Res. 2020 Jan 1;26(1):35-45. doi: 10.1158/1078-0432.CCR-19-2023.
Miguel Quintela-Fandino 1 2 3,  Serafín Morales 4,  Alfonso Cortés-Salgado 5,  Luis Manso 6,  Juan V Apala 7 2,  Manuel Muñoz 7,  Ariadna Gasol Cudos 4,  Joel Salla Fortuny 4,  María Gion 5,  Antonio Lopez-Alonso 7,  Javier Cortés 8 9,  Juan Guerra 2,  Diego Malón 2,  Eduardo Caleiras 10,  Francisca Mulero 11,  Silvana Mouron 7
Affiliations

Affiliations

  • 1 Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center, Madrid, Spain. mquintela@cnio.es.
  • 2 Medical Oncology, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain.
  • 3 Medical Oncology, Hospital Universitario Quiron, Pozuelo de Alarcon, Spain.
  • 4 Medical Oncology, Hospital Universitari Arnau Vilanova, Lleida, Spain.
  • 5 Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
  • 6 Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • 7 Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center, Madrid, Spain.
  • 8 ION Institute of Oncology, Quironsalud Group - Madrid and Barceona, Spain.
  • 9 Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • 10 Histopathology Unit, CNIO - Spanish National Cancer Research Center, Madrid, Spain.
  • 11 Molecular Imaging Unit, CNIO - Spanish National Cancer Research Center, Madrid, Spain.
PMID: 31597662 DOI: 10.1158/1078-0432.CCR-19-2023
Abstract

Purpose: We previously demonstrated that mitochondrial inhibitors' efficacy was restricted to a metabolic context in which mitochondrial respiration was the predominant energy source, a situation achievable by inducing vascular normalization/hypoxia correction with antiangiogenics. Vascular normalization can be tracked with 2[18F]fluoro-2-deoxy-d-glucose (FDG)-PET. We tested the efficacy of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early breast Cancer.

Patients and methods: Treatment-naïve HER2-negative patients with T > 1 cm (any N) underwent a breast-centered 18F-fluorodeoxyglucose (FDG)-PET (day 1) and received a single dose of bevacizumab (15 mg/kg), followed by a second FDG-PET (day 8). Patients were then randomized (1:1) to Arm A (ME-344 10 mg/kg intravenous on days 8, 15, and 21) or Arm B (placebo). Tumors were biopsied on days 0 and 29. Succinate dehydrogenase Enzyme histochemistry (SDH-EHC), confocal microscopy of vessel architecture, and HIF1α staining were performed in pre- and posttreatment biopsies to assess the pharmacodynamics, vessel normalization, and tissue re-oxygenation by bevacizumab, respectively.

Results: ME-344 displayed significant biological activity versus placebo: compared with a 186% increase in Arm B, Ki67 decreased by 23.4% from days 0 to 28 in Arm A (P < 0.001) (N = 42 patients). FDG-PET predicted vascular normalization in about one-third of the patients in each arm, which was confirmed using confocal microscopy and HIF1α staining. In the subgroup with vascular normalization, ME-344 induced a Ki67 decrease of 33.4% (placebo: 11.8 increase). SDH-EHC suggested on-target effects of ME-344.

Conclusions: ME-344 has significant biological antitumor activity in HER2-negative breast Cancer, particularly after induction of vascular normalization and tissue reoxygenation with bevacizumab.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z